Ensign Peak Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$136M Sell
4,829,237
-528,187
-10% -$14.1M 0.25% 87
2025
Q4
$133M Buy
5,357,424
+233,752
+5% +$5.89M 0.24% 87
2025
Q3
$131M Sell
5,123,672
-84,102
-2% -$2.08M 0.21% 96
2025
Q2
$126M Sell
5,207,774
-1,094,238
-17% -$25.5M 0.22% 97
2025
Q1
$160M Sell
6,302,012
-142,999
-2% -$3.74M 0.31% 72
2024
Q4
$171M Buy
6,445,011
+1,383,305
+27% +$37.5M 0.3% 63
2024
Q3
$146M Sell
5,061,706
-102,063
-2% -$2.98M 0.26% 78
2024
Q2
$144M Sell
5,163,769
-261,578
-5% -$7.2M 0.26% 75
2024
Q1
$151M Buy
5,425,347
+363,032
+7% +$10.1M 0.28% 74
2023
Q4
$146M Buy
5,062,315
+1,771,860
+54% +$53.6M 0.29% 74
2023
Q3
$109M Sell
3,290,455
-248,974
-7% -$8.8M 0.23% 91
2023
Q2
$130M Sell
3,539,429
-1,797,819
-34% -$70M 0.26% 86
2023
Q1
$218M Sell
5,337,248
-584,788
-10% -$25.3M 0.47% 54
2022
Q4
$303M Sell
5,922,036
-521,478
-8% -$25M 0.68% 31
2022
Q3
$282M Buy
6,443,514
+607,762
+10% +$29.5M 0.7% 34
2022
Q2
$306M Buy
5,835,752
+80,888
+1% +$4.12M 0.73% 30
2022
Q1
$298M Sell
5,754,864
-945,041
-14% -$49M 0.61% 35
2021
Q4
$396M Buy
6,699,905
+1,775,904
+36% +$88M 0.76% 22
2021
Q3
$212M Buy
4,924,001
+761,388
+18% +$33.7M 0.44% 53
2021
Q2
$163M Sell
4,162,613
-48,755
-1% -$1.9M 0.33% 83
2021
Q1
$153M Sell
4,211,368
-72,326
-2% -$2.57M 0.33% 83
2020
Q4
$158M Buy
4,283,694
+1,530,414
+56% +$56.1M 0.36% 69
2020
Q3
$95.9M Sell
2,753,280
-29,077
-1% -$1.02M 0.24% 83
2020
Q2
$86.3M Buy
2,782,357
+66,129
+2% +$2.25M 0.23% 88
2020
Q1
$84.1M Buy
2,716,228
+545,160
+25% +$18.6M 0.28% 82
2019
Q4
$80.7M Buy
+2,171,068
New +$77.3M 0.21% 91

Other funds holding PFE

Ensign Peak Advisors's PFE Position: Q1 2026 in Review

Ensign Peak Advisors reduced its Pfizer (PFE) stake by 9.9% in Q1 2026, selling an estimated $14.1M and leaving 4,829,237 shares worth $136M. The position accounts for 0.25% of the portfolio, ranked #87.

Ensign Peak Advisors first reported a position in PFE in Q4 2019 and has held it in 26 quarters since. The position peaked at $396M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Ensign Peak Advisors held 4,829,237 shares of Pfizer worth $136M as of Q1 2026.
  • Ensign Peak Advisors sold 528,187 Pfizer shares in Q1 2026, an estimated $14.1M.
  • Pfizer made up 0.25% of Ensign Peak Advisors's portfolio in Q1 2026, its #87 holding.
  • Ensign Peak Advisors first reported a position in Pfizer in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Pfizer position peaked at $396M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.